Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818766 | 0.85 | LAP3 (0.44) | LAP3MMP2 | |
| SCHEMBL8842566 | 0.84 | — | — | |
| SCHEMBL4823064 | 0.82 | FDPS (0.46) | LAP3 | |
| SCHEMBL23528237 | 0.80 | — | — | |
| SCHEMBL779153 | 0.80 | LAP3 (0.31) | LAP3 | |
| SCHEMBL646399 | 0.79 | FDPS (0.50) | LAP3LPAR2LPAR3 | |
| SCHEMBL2358292 | 0.78 | FDPS (0.40) | LAP3KDM4EMMP2THRBMAPK1 | |
| SCHEMBL3278676 | 0.76 | TSHR (0.48) | THRBMAPK1HSD17B10 | |
| SCHEMBL10712824 | 0.76 | — | — | |
| SCHEMBL4410388 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011141934-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF HMG-COA REDUCTASE INHIBITORS | MATRIX LABORATORIES LTD. (IN) | 2011-11-17 | — | — | WO | claimed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | claimed |
| EP-1603906-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ALPHA V BETA 3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | claimed |
| WO-2004078109-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | claimed |
| EP-2311820-A1 | Process for the purification of latanoprost by HPLC | Resolution Chemicals Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| US-7498458-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1603906-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ALPHA V BETA 3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261374-A1 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED | 2005-11-24 | — | — | US | disclosed |
| US-20040249172-A1 | Process for the preparationof prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
| WO-2004078109-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4628110-A | Novel 9-substituted carbacyclin analogs | THE UPJOHN COMPANY (US) | 1986-12-09 | — | — | US | disclosed |
| EP-0086611-B1 | 9-SUBSTITUTED CARBACYCLIN ANALOGUES | THE UPJOHN COMPANY (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4590297-A | Novel 9-substituted carbacyclin analogs | THE UPJOHN COMPANY (US) | 1986-05-20 | — | — | US | disclosed |
| US-4588823-A | 9-substituted carbacyclin analogs | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4533749-A | 9-Substituted carbacyclin analogs | THE UPJOHN COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| US-4487961-A | ANTIULCER, ANTIASTHMA, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
| US-4487960-A | 9-Substituted carbacyclin analogs | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249172-A1 | Process for the preparationof prostaglandins and analogues thereof | PTGIS, PTGES, PTGES2 | LAP3 2336/4885KDM4E 4076/4885MMP2 1551/4885 |
| US-20050261374-A1 | Process for the preparation of prostaglandins and analogues thereof | PTGIS, PTGES, PTGES2 | LAP3 2146/4885KDM4E 4075/4885MMP2 1526/4885 |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | AVPR1A, AVPR1B, ADRB3 | LAP3 1774/4885KDM4E 4203/4885MMP2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.